YZ9 - C12H10O5 - Bertin Bioreagent

Confirm delete?

YZ9

Zoom

Cat No: 15352

Biochemicals - Small Molecule Inhibitors

Cells that are rapidly proliferating or hypoxic emphasize glycolysis over oxidative phosphorylation to meet energy needs.{22136,26415} During glycolysis, fructose 6-phosphate (F6P) is phosphorylated by 6-phosphofructo-2-kinases (PFKs) to generate fruct...

This product can only be bought through Cayman Chemical. Please contact us.

Product Overview
Data
Downloads
About Cayman

Territorial Availability: Available through Bertin Technologies only in France

Synonyms:

7-hydroxy-2-ozo-2H-1-benzopyran-3-carboxylic acid, ethyl ester

Correlated keywords:

1259293-?98-?5 biochemicals metabolism hypoxia inhibitors inhibits inhibitions cells biology cancers potent PFKFB 6-phosphofructo-2-kinases PFKs PFKFB-3 PFKFB3 3 F6P permeable growth HeLa fructose 6-phosphate glycolysis enzymes YZ9 YZ-9 in vitro

Product Overview:
Cells that are rapidly proliferating or hypoxic emphasize glycolysis over oxidative phosphorylation to meet energy needs.{22136,26415} During glycolysis, fructose 6-phosphate (F6P) is phosphorylated by 6-phosphofructo-2-kinases (PFKs) to generate fructose 2,6-bisphosphate. As PFK family members also mediate the reverse reaction as fructose 2,6-bisphosphatases, these enzymes are known as PFKFB family members. Notably, PFKFB3 is overexpressed in a wide variety of cancer cell lines.{27006} YZ9 is a potent inhibitor of PFKFB3, with an IC50 value of 183 nM in vitro.{27006} It avidly competes with F6P at PFKFB3 (Ki = 94 nM).{27006} YZ9 is also cell permeable, inhibiting the growth of HeLa cells with a GI50 value of 2.7 µM.{27006}

Size	5 mg
Shipping	dry ice
CAS Number	6093-71-6
Molecular Formula	C₁₂H₁₀O₅
SMILES	O=C1C(C(OCC)=O)=CC2=CC=C(O)C=C2O1
Molecular Weight	234,2
Formulation	A crystalline solid
Purity	≥98%
Custom Code	2918.99
UNSPSC code	12352100

Technical File

MSDS

Click here to ask for your quote and get 15% off Cayman's products.

Cayman Chemical's mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.

Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.

Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.

Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.

Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009

Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.